Drugs / DMB-3115
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04785326 | Apr 2021 → Feb 2022 | psoriasis | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DMB-3115 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04785326 ↗ |
| Route | Subcutaneous | “45mg or 90mg dose subcutaneous administration” NCT04785326 ↗ |